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background:  Previous studies have suggested that the deterioration of renal function increases the risk of major adverse clinical events 
not only in culprit lesions but also in non-culprit lesions (NCL) after percutaneous coronary intervention (PCI) However, little is known about 
coronary atherosclerotic plaque change of NCL after culprit PCI in each stage of chronic kidney disease (CKD). This study evaluated serial 
coronary plaque change of NCL in patients with different stages of CKD using integrated backscatter intravascular ultrasound (IB-IVUS).
methods:  In 113 patients (113 NCLs) underwent both IVUS-guided PCI and follow-up IVUS, volumetric IVUS analyses were performed at 
proximal NCL in de novo target vessels post PCI and at 8-month follow-up. NCLs were divided into 4 groups based on baseline CKD stage: 
stage1, n=18; stage2, n=43; stage3, n=29; and stage4-5, n=24. We compared serial changes of plaque burden and composition among 
groups under standard medical therapy.
results:  Baseline patient characteristics showed age and diabetes were higher in stage3 than the other groups, but otherwise there was 
no significant difference among groups. Plaque volume was greater in stage4-5 than the other groups. (p =0.009) at baseline. Plaque 
progression occurred in stage3 (+ 4.6 mm3, p <0.001) and stage4-5 (+ 9.8 mm3, p <0.001), whereas plaque regression occurred in stage1 
(- 5.4 mm3, p =0.002) and stage2 (- 3.2 mm3, p=0.001). Plaque volume change was correlated with eGFR. (p<0.0001). Regarding IB-
IVUS analyses, lipid plaque increased in stage3 (+ 4.6 mm3, p <0.001) and stage4-5 (+ 5.4 mm3, p <0.001), but decreased in stage2 
(- 2.7 mm3, p <0.05). Fibrotic plaque also increased in stage4-5 (+ 3.4 mm3, p <0.001). Multivariate analysis revealed CKD staging was an 
independent predictor of plaque progression.
Conclusion:  Advanced-stage CKD were associated with coronary plaque progression characterized by greater lipid and fibrotic plaque 
volumes in NCL under standard medical therapy after culprit PCI. Strict risk management should be required to prevent subsequent 
coronary events in those patients.
